Correlation Between Neximmune and Climb Bio
Can any of the company-specific risk be diversified away by investing in both Neximmune and Climb Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neximmune and Climb Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neximmune and Climb Bio, you can compare the effects of market volatilities on Neximmune and Climb Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neximmune with a short position of Climb Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neximmune and Climb Bio.
Diversification Opportunities for Neximmune and Climb Bio
Poor diversification
The 3 months correlation between Neximmune and Climb is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding Neximmune and Climb Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Climb Bio and Neximmune is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neximmune are associated (or correlated) with Climb Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Climb Bio has no effect on the direction of Neximmune i.e., Neximmune and Climb Bio go up and down completely randomly.
Pair Corralation between Neximmune and Climb Bio
If you would invest 243.00 in Neximmune on September 22, 2024 and sell it today you would earn a total of 0.00 from holding Neximmune or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 4.76% |
Values | Daily Returns |
Neximmune vs. Climb Bio
Performance |
Timeline |
Neximmune |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Climb Bio |
Neximmune and Climb Bio Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Neximmune and Climb Bio
The main advantage of trading using opposite Neximmune and Climb Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neximmune position performs unexpectedly, Climb Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Climb Bio will offset losses from the drop in Climb Bio's long position.Neximmune vs. ZyVersa Therapeutics | Neximmune vs. Palisade Bio | Neximmune vs. Unicycive Therapeutics | Neximmune vs. Immix Biopharma |
Climb Bio vs. Dogwood Therapeutics, | Climb Bio vs. Eupraxia Pharmaceuticals Common | Climb Bio vs. CERo Therapeutics Holdings | Climb Bio vs. Opus Genetics, |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Complementary Tools
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Transaction History View history of all your transactions and understand their impact on performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |